reports
Achaogen, Inc. Announces Results of Auction for Substantially All Comp...
Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substantially all of its assets for aggregate cash consideration of approximately $16 million, plus potential royalties and assumption of certain contractual liabilities, subject to negotiation and execution of binding definitive ...
Achaogen Plans for Near-Term Sale Using Structured Process Through Cha...
Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code Bidding process and auction projected to conclude June 2019 SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today that it has filed a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Achaogen ha...
- Ashiq Mubarack
- David Nierengarten
- Robert Driscoll
Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results a...
Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update -- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference call today at 4:30 p.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negati...
- Ashiq Mubarack
- David Nierengarten
- Jeffrey La Rosa
- Liana Moussatos
- Robert Driscoll
- Shveta Dighe
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IRWD IRONWOOD PHARMACEUTICALS INC. CLASS A
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
AKAO ACHAOGEN INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
BOLD AUDENTES THERAPEUTICS INC.
MGEN MIRAGEN THERAPEUTICS
SRRA SIERRA ONCOLOGY
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
ORTX INC.
HARP ORCHARD THERAPEUTICS
FENC HARPOON THERAPEUTICS
FENNEC PHARMA
- Jonathan Moreland
STON STONEMOR INC.
KR KROGER CO.
HIIQ HEALTH INSURANCE INNOVATIONS INC
DFRG DEL FRISCO'S RESTAURANT GROUP
AXO ABRAXAS PETROLEUM CORP.
AKAO ACHAOGEN INC.
NEWT NEWTEK BUSINESS SERVICES INC.
SITE SITEONE LANDSCAPE SUPPLY INC.
SNAP SNAP INC. CLASS A
SFIX STITCH FIX CLASS A
FSK FS KKR CAPITAL CORP
- Jonathan Moreland
WDC WESTERN DIGITAL CORPORATION
URBN URBAN OUTFITTERS INC.
TNAV TELENAV
SYNL SYNALLOY CORP.
STON STONEMOR INC.
RPT RAMCO-GERSHENSON PROPERTIES TRUST
PRGX PRGX GLOBAL
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
OCUL OCULAR THERAPEUTIX
LION FIDELITY SOUTHERN CORP.
LGND LIGAND PHARMACEUTICALS INCORPORATED
KOP KOPPERS HOLDINGS INC.
HCI HCI GROUP INC.
GARS GARRISON CAPITAL INC.
FFIN FIRST FINANCIAL BANKSHARES INC
EVH EVOLENT HEALTH INC CLASS A
ESGR ENSTAR GROUP LIMITED
DFRG DEL FRISCO'S RESTAURANT GROUP
CVS CVS HEALTH CORPORATION
CVRS CORINDUS VASCULAR ROBOTICS
CSU CAPITAL SENIOR LIVING CORPORATION
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC
CORT CORCEPT THERAPEUTICS INCORPORATED.
BECN BEACON ROOFING SUPPLY INC.
ATVI ACTIVISION BLIZZARD INC.
ARTX AROTECH
AKAO ACHAOGEN INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ACRX ACELRX PHARMACEUTICALS
ACRE ARES COMMERCIAL REAL ESTATE
ATEC ALPHATEC HOLDINGS INC.
ATRO ASTRONICS CORPORATION
CERC CERECOR INC
CULP CULP INC.
MGM MGM RESORTS INTERNATIONAL
FIZZ NATIONAL BEVERAGE CORP.
OTEL OTELCO INC
PMD PSYCHEMEDICS CORP.
IDSY I.D. SYSTEMS INC.
HAIN THE HAIN CELESTIAL GROUP
RIBT INC.
WOW RICEBRAN TECHNOLOGIES
CGBD WIDEOPENWEST INC.
ODT TCG BDC
APLS ODONATE THERAPEUTICS INC
MAXR APELLIS PHARMACEUTICALS
SFIX MAXAR TECHNOLOGIES INC.
RDVT STITCH FIX CLASS A
AMRX RED VIOLET
RNDB AMNEAL PHARMACEUTICALS INC. CLASS A
REZI RANDOLPH BANCORP
CTT RESIDEO TECHNOLOGIES
INC.
WELLS TIMBERLAND REIT
INC.
- Ashiq Mubarack
- David Nierengarten
- Jeffrey La Rosa
- Liana Moussatos
- Robert Driscoll
- Shveta Dighe
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
VYGR VOYAGER THERAPEUTICS INC.
STML STEMLINE THERAPEUTICS INC
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IRWD IRONWOOD PHARMACEUTICALS INC. CLASS A
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
AKAO ACHAOGEN INC.
AIMT AIMMUNE THERAPEUTICS INC
AGTC APPLIED GENETIC TECHNOLOGIES
ABUS ARBUTUS BIOPHARMA CORP.
ALPN ALPINE SELECT AG
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
MRUS MERUS B V
BOLD AUDENTES THERAPEUTICS INC.
MGEN MIRAGEN THERAPEUTICS
SRRA SIERRA ONCOLOGY
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
NBRV NABRIVA THERAPEUTICS PLC
MRSN MERSANA THERAPEUTICS
SYBX SYNLOGIC
GTHX G1 THERAPEUTICS
VRNA VERONA PHARMA ADS
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
RCUS ARCUS BIOSCIENCES
TORC RESTORBIO INC
UMRX UNUM THERAPEUTICS
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
ORTX INC.
HARP ORCHARD THERAPEUTICS
FENC HARPOON THERAPEUTICS
FENNEC PHARMA
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Yea...
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019 SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter financial results on Thursday, March 28, 2019 after the open of financial markets. Following the results announcement, company management will host a conference cal...
Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results...
Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine -- ZEMDRI is the only once-daily aminoglycoside therapy FDA-approved for use in complicated urinary tract infections (cUTI) -- -- Treatment with ZEMDRI resulted in a greater than four-fold reduction in relapse of cUTI clinical symptoms compared to meropenem at Day 28 -- SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to a...
Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Result...
Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) study of plazomicin in a Letter to the Editor. In this published ...
Achaogen Announces Closing of $15 Million Underwritten Public Offering
Achaogen Announces Closing of $15 Million Underwritten Public Offering SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to ...
Achaogen Announces Presentations at Two Upcoming Investor Healthcare C...
Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences -- Leerink February 27, 2019 at 9:30 a.m. ET -- -- Cowen March 12, 2019 at 12:00 p.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the following investor conferences: 8th Annual Leerink Global Healthcare Conference (New York) on Febr...
Achaogen Announces Pricing of $15 Million Underwritten Public Offering
Achaogen Announces Pricing of $15 Million Underwritten Public Offering SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its ...
Achaogen Announces Proposed Public Offering of Common Stock
Achaogen Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriter of the offering a 30-day option to purchase...
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) ...
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield -- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has responded to a Request for Information (RFI) regarding antibacterial products with the potential to ...
Achaogen Provides Update on Corporate Progress and Key Preliminary Fou...
Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results -- Company provides update on ZEMDRI® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today shared certain key preliminary unaudite...
- Jonathan Moreland
VEC VECTRUS
SYNL SYNALLOY CORP.
SPKE SPARK ENERGY INC-CLASS A
SFE SAFEGUARD SCIENTIFICS INC.
QTNT QUOTIENT LTD
PENN PENN NATIONAL GAMING INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
OCUL OCULAR THERAPEUTIX
LKFN LAKELAND FINANCIAL CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HCI HCI GROUP INC.
FIT FITBIT INC. CLASS A
FB FACEBOOK INC. CLASS A
DISH DISH NETWORK CORPORATION CLASS A
VPA1 AVEO PHARMACEUTICALS INC.
ARMK ARAMARK
AKAO ACHAOGEN INC.
AFG AMERICAN FINANCIAL GROUP INC.
ACRX ACELRX PHARMACEUTICALS
THO THOR INDUSTRIES INC.
WPG WASHINGTON PRIME GROUP INC.
SQBG SEQUENTIAL BRANDS GROUP INC
VSM VERSUM MATERIALS INC.
HOME AT HOME GROUP INC.
RIBT RICEBRAN TECHNOLOGIES
ANAB ANAPTYSBIO INC.
CGBD TCG BDC
NMRK NEWMARK GROUP INC
AROC ARCHROCK INC.
TALO TALOS ENERGY INC.
BBDC BARINGS BDC INC.
Achaogen Announces FDA Clearance and Launch of the Thermo Scientific Q...
Achaogen Announces FDA Clearance and Launch of the Thermo Scientific QMS Plazomicin Immunoassay Thermo Fisher Scientific and Achaogen jointly develop new assay to enable Therapeutic Drug Management SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) has provid...
Achaogen Announces Multiple Plazomicin Presentations at the American S...
Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced upcoming presentations on the economic value of plazomicin and the costs associated with in-hospital treatment of bloodstream infections and sepsis at the ASHP Midyear 2018 Clini...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.